If you missed the first poster session, you can still make it to this evening's! One of our poster abstracts was selected for the top 100 #SITC24!
Dragonfly Therapeutics, Inc.
Biotechnology Research
Waltham, MA 13,208 followers
About us
Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing therapies that use its novel multispecific antibody technology to harness the body's immune system to bring breakthrough treatments to patients. In addition to its wholly owned clinical assets, Dragonfly has a deep pipeline of wholly owned preclinical candidates discovered using its proprietary platform, as well as productive collaborations with Merck, AbbVie, Gilead and Bristol Myers Squibb in a broad range of disease areas. For more information, email info@dragonflytx.com.
- Website
-
http://dragonflytx.com/
External link for Dragonfly Therapeutics, Inc.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Waltham, MA
- Type
- Privately Held
- Founded
- 2016
- Specialties
- immuno-oncology
Locations
-
Primary
Get directions
Waltham, MA 02451, US
Employees at Dragonfly Therapeutics, Inc.
Updates
-
Dragonfly Therapeutics is presenting 2 posters, today, at the Society for #Immunotherapy of #Cancer (#SITC24) Annual Conference! Swing by during the poster session and learn more. https://lnkd.in/eYMqKnsZ
-
-
Proudly presenting our Phase 1/1b, First-in-Human, multi-part study of DF6215, an engineered IL-2Rα-active agonist for advanced solid tumors, in the Developmental Therapeutics-Immunotherapy poster session at American Society of Clinical Oncology (ASCO) with Benedito A. Carneiro, MD, MS, Brown University #ASCO24
-
-
Dragonfly is in Chicago! #ASCO24
-
-
We have entered into a clinical collaboration with Merck to evaluate DF9001, our EGFR immune engager, in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with advanced solid tumors expressing EGFR. https://lnkd.in/eErs3u3n
-
We're super proud to be in the top 3 Best Biotech Startup Employers in the Boston area by @Forbes for 2024! 3000 privately-held Startup companies were evaluated on 3 primary criteria: company reputation, employee satisfaction and growth (each Startup must also have been started from scratch, founded between 2014 and 2021, headquartered in the U.S., and have more than 50 employees). https://lnkd.in/gic_9qPz
Meet America’s Best Startup Employers 2024
forbes.com
-
First Patient dosed in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303 in solid tumors. This is the sixth TriNKET® and the eighth Dragonfly drug to enter into clinical trials! https://lnkd.in/dXibkKrc
Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303
prnewswire.co.uk
-
We are thrilled to announce a new clinical collaboration with #Gilead, combining DF1001, our HER-2 immune engager, with Trodelvy, Gilead's Trop-2-directed antibody drug conjugate (ADC), for two cancer indications. https://lnkd.in/e4TQwHbC
Dragonfly Announces Clinical Collaboration Exploring Combinations of Dragonfly's DF1001 HER-2 TriNKET® with Gilead's Trodelvy® in two Cancer Indications
prnewswire.com
-
First patient dosed in a Phase 1/1b clinical trial of our novel IL-2 cytokine, DF6215, the 7th Dragonfly-developed drug to enter into clinical trials! https://lnkd.in/gm5PA4Gd
Dragonfly Therapeutics Initiates Phase 1/1b Study of its IL-2 Immunotherapy in Patients with Advanced Solid Tumors | BioSpace
biospace.com